Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

BUY
$1.19 - $2.09 $366,271 - $643,283
307,791 Added 81.91%
683,557 $861,000
Q4 2022

Feb 14, 2023

SELL
$1.67 - $2.35 $107,426 - $151,168
-64,327 Reduced 14.62%
375,766 $699,000
Q3 2022

Nov 14, 2022

BUY
$1.81 - $2.76 $26,047 - $39,719
14,391 Added 3.38%
440,093 $850,000
Q2 2022

Aug 15, 2022

BUY
$1.34 - $5.34 $28,310 - $112,818
21,127 Added 5.22%
425,702 $885,000
Q1 2022

May 16, 2022

SELL
$4.58 - $6.8 $755,434 - $1.12 Million
-164,942 Reduced 28.96%
404,575 $2.06 Million
Q4 2021

Feb 14, 2022

SELL
$5.23 - $7.18 $1.81 Million - $2.49 Million
-346,134 Reduced 37.8%
569,517 $3.66 Million
Q3 2021

Nov 12, 2021

SELL
$5.94 - $8.75 $1.35 Million - $1.99 Million
-227,953 Reduced 19.93%
915,651 $5.67 Million
Q2 2021

Aug 16, 2021

BUY
$7.54 - $9.79 $1.31 Million - $1.7 Million
173,312 Added 17.86%
1,143,604 $5.7 Million
Q1 2021

May 17, 2021

BUY
$4.76 - $11.25 $3.27 Million - $7.72 Million
686,483 Added 241.88%
970,292 $4.83 Million
Q4 2020

Feb 16, 2021

SELL
$2.43 - $5.42 $51,022 - $113,803
-20,997 Reduced 6.89%
283,809 $1.37 Million
Q3 2020

Nov 16, 2020

SELL
$2.3 - $3.72 $255,322 - $412,957
-111,010 Reduced 26.7%
304,806 $759,000
Q2 2020

Aug 14, 2020

SELL
$1.33 - $3.63 $473,868 - $1.29 Million
-356,292 Reduced 46.15%
415,816 $1.29 Million
Q1 2020

May 14, 2020

SELL
$1.27 - $2.33 $239,944 - $440,213
-188,933 Reduced 19.66%
772,108 $1.11 Million
Q4 2019

Feb 14, 2020

BUY
$1.3 - $2.72 $167,388 - $350,227
128,760 Added 15.47%
961,041 $1.95 Million
Q3 2019

Nov 14, 2019

BUY
$1.93 - $4.21 $484,410 - $1.06 Million
250,990 Added 43.18%
832,281 $1.96 Million
Q2 2019

Aug 15, 2019

BUY
$2.05 - $4.32 $1.19 Million - $2.51 Million
581,291 New
581,291 $2.51 Million

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $78.9M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.